Health service of Balearic Islands announced that it would offer for the first time vaccine against respiratory syncytial virus (RSV) children born or 6 months of age between October and March, as recommended by the National Public Health Commission.
As reported, the picture is as follows. single dose except for children with certain risks who need to get two.
The virus responsible for most bronchiolitis in children
The approved drug is nirsevimab, which is indicated for passive immunization against RSV, the virus responsible for most bronchiolitis in infants and more than half of hospitalizations and admissions to intensive care units for respiratory problems in children under 6 months of age.
RSV has also been associated with respiratory diseases bacteria and with the subsequent development bronchial hyperactivity and asthma. The Ministry of Health has announced an urgent processing of the supply contract given the need to have sufficient doses to start the campaign. The initial term of the contract will be valid until June 30, 2024and may be extended for a maximum of two years.
Although the information contained in Redacción Médica may contain statements, data or notes from medical institutions or professionals, it is edited and prepared by journalists. We encourage the reader to consult with a healthcare professional for any health-related issues.